Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of stable moderate to severe COPD as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, 2008; postbronchodilator FEV1/FVC \< 70%, and postbronchodilator FEV1 ≥ 30% and \< 80% predicted~* Current or former cigarette smokers~Exclusion Criteria:~* Patients who have been hospitalized for an acute COPD exacerbation within 3 months before the first visit~* Respiratory tract infection or COPD exacerbation in the 6 weeks before Visit 1~* Patient with any clinically significant respiratory conditions other than COPD, cardiovascular conditions or mental illness~* History or presence of asthma verified from medical records~* Chronic use of oxygen therapy greater than or equal to 15 hours per day~* Patient with uncontrolled infection due to HIV and/or active hepatitis~* Patients with a history of hypersensitivity reaction to inhaled anticholinergics~* Patients with clinically significant cardiovascular conditions, including myocardial infarction during the previous 6 months, newly diagnosed arrhythmia within the previous 3 months, unstable angina, unstable arrhythmia that had required changes in pharmacological therapy or other intervention.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide 200 μg dose twice per day, inhaled for 12 weeks of treatment At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks
- 2 (Type: EXPERIMENTAL): Aclidinium bromide 400 μg dose twice per day, inhaled for 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 400 μg will continue to receive open label 400µg aclidinium bromide for 40 weeks
- 3 (Type: PLACEBO_COMPARATOR): Dose-match placebo, oral inhalation twice per day for 12 weeks of treatment. At week 12, patients who were on placebo will receive open label 400µg aclidinium bromide for 40 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).